Current and emerging treatment options for myopic choroidal neovascularization

Leila El Matri, Ahmed Chebil, Fedra Kort Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia Abstract: Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	El Matri L, Chebil A, Kort F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/005ac5f1dc0446f0aa68ddca5c818d84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:005ac5f1dc0446f0aa68ddca5c818d84
record_format	dspace
spelling	oai:doaj.org-article:005ac5f1dc0446f0aa68ddca5c818d842021-12-02T01:37:44ZCurrent and emerging treatment options for myopic choroidal neovascularization1177-5483https://doaj.org/article/005ac5f1dc0446f0aa68ddca5c818d842015-04-01T00:00:00Zhttp://www.dovepress.com/current-and-emerging-treatment-options-for-myopic-choroidal-neovascula-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Leila El Matri, Ahmed Chebil, Fedra Kort Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia Abstract: Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger than 50 years of age. There are different treatments for myopic CNV (mCNV), with 5- to 10-year outcomes currently. Chorioretinal atrophy is still the most important determinant factor for visual outcome. The purpose of this study is to provide an overview of the current treatments for mCNV, including laser, surgical management, verteporfin photodynamic therapy, and mainly anti-vascular endothelial growth factor therapy. Emerging treatment options are also discussed. Keywords: myopia, choroidal neovascularization, current treatment, emerging treatmentEl Matri LChebil AKort FDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 733-744 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 El Matri L Chebil A Kort F Current and emerging treatment options for myopic choroidal neovascularization
description	Leila El Matri, Ahmed Chebil, Fedra Kort Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia Abstract: Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger than 50 years of age. There are different treatments for myopic CNV (mCNV), with 5- to 10-year outcomes currently. Chorioretinal atrophy is still the most important determinant factor for visual outcome. The purpose of this study is to provide an overview of the current treatments for mCNV, including laser, surgical management, verteporfin photodynamic therapy, and mainly anti-vascular endothelial growth factor therapy. Emerging treatment options are also discussed. Keywords: myopia, choroidal neovascularization, current treatment, emerging treatment
format	article
author	El Matri L Chebil A Kort F
author_facet	El Matri L Chebil A Kort F
author_sort	El Matri L
title	Current and emerging treatment options for myopic choroidal neovascularization
title_short	Current and emerging treatment options for myopic choroidal neovascularization
title_full	Current and emerging treatment options for myopic choroidal neovascularization
title_fullStr	Current and emerging treatment options for myopic choroidal neovascularization
title_full_unstemmed	Current and emerging treatment options for myopic choroidal neovascularization
title_sort	current and emerging treatment options for myopic choroidal neovascularization
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/005ac5f1dc0446f0aa68ddca5c818d84
work_keys_str_mv	AT elmatril currentandemergingtreatmentoptionsformyopicchoroidalneovascularization AT chebila currentandemergingtreatmentoptionsformyopicchoroidalneovascularization AT kortf currentandemergingtreatmentoptionsformyopicchoroidalneovascularization
_version_	1718402936696995840

Current and emerging treatment options for myopic choroidal neovascularization

Ejemplares similares